Evidence explainerVaginal Health: BV & Yeast

Recurrent Yeast Infections: Fluconazole, Boric Acid and Oteseconazole Compared

Recurrent yeast infection means three or more episodes in a year. Weekly fluconazole kept 91% of women symptom-free for 6 months in the main trial, but most relapsed after stopping. Many women who self-treat do not have a yeast infection at all.

By Kymata Health editorial teamPublished October 10, 2026Last verified October 10, 2026

Medical review pending. Written by our editorial team from the studies and documents cited below; a credentialed clinician has not reviewed it yet. Educational only, not medical advice.

Key takeaways

  • The CDC defines recurrent vulvovaginal candidiasis as 3 or more symptomatic episodes in under a year; it affects fewer than 5% of women [1].
  • Only 33.7% of women who self-diagnosed a yeast infection had one; others had BV, mixed infections or nothing [2].
  • Weekly fluconazole for 6 months kept 90.8% of women disease-free at 6 months vs 35.9% on placebo, falling to 42.9% vs 21.9% at 12 months [3].
  • Oteseconazole (Vivjoa) cut culture-verified recurrence through week 48 to 4 to 7% vs 39 to 43% with placebo, but it is approved only for women who cannot have children [4].

Confirm it is yeast

In a 2002 study of 95 women buying over-the-counter antifungals for a self-diagnosed yeast infection, only 33.7% actually had a yeast infection; 18.9% had BV, 21.1% had mixed vaginitis and 13.7% had normal findings [2]. A previous clinician diagnosis did not make women better at self-diagnosis [2].

The CDC recommends clinical evaluation and testing for anyone whose symptoms persist after an over-the-counter product or come back within 2 months, and culture to identify non-albicans species in recurrent cases [1].

Weekly fluconazole

The CDC recommends a longer initial course, such as fluconazole every third day for 3 doses, followed by weekly fluconazole for 6 months as maintenance [1].

In the main trial, the proportion disease-free at 6, 9 and 12 months was 90.8%, 73.2% and 42.9% with weekly fluconazole vs 35.9%, 27.8% and 21.9% with placebo [3]. The authors noted long-term cure remains difficult [3]. A 2022 Cochrane review found most trials of recurrent yeast treatment were small (under 100 women) [5].

Boric acid

For non-albicans yeast that recurs, the CDC lists 600 mg of boric acid in a gelatin capsule placed vaginally once daily for 3 weeks, with cure rates around 70% [1].

A 2011 review of 14 studies, mostly case series, found cure rates of 40 to 100%, no significant difference in recurrence rates, and side effects such as vaginal burning in under 10% of cases [6].

Oteseconazole (Vivjoa)

The FDA approved oteseconazole on April 26, 2022 based on 3 trials in 871 women with recurrent yeast infections [4]. In the two placebo-controlled trials, 6.7% and 3.9% of women on oteseconazole had at least one culture-verified episode through week 48, vs 42.8% and 39.4% on placebo [4].

It is indicated only for women who are not of reproductive potential; the FDA says it may harm an unborn baby and is not recommended in pregnancy or breastfeeding; the most common side effects were headache and nausea [4].

Quick answers

Are probiotics a good way to prevent yeast infections?

The CDC says no substantial evidence supports probiotics for treating yeast infections [1]. See our vaginal probiotics guide for the trial details.

Can I take fluconazole while pregnant?

The CDC recommends only topical azoles, for 7 days, in pregnancy, because a single 150 mg fluconazole dose may be linked to miscarriage and birth defects [1].

More in Vaginal Health: BV & Yeast

References

  1. [1]Vulvovaginal Candidiasis (VVC): Sexually Transmitted Infections Treatment Guidelines, 2021. Centers for Disease Control and Prevention, 2021.
  2. [2]Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol, 2002. PMID 11864668
  3. [3]Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med, 2004. PMID 15329425
  4. [4]Drug Trials Snapshots: VIVJOA (oteseconazole). U.S. Food and Drug Administration, 2024.
  5. [5]Treatment for recurrent vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev, 2022. PMID 35005777
  6. [6]Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt), 2011. PMID 21774671

Dietary supplements are not intended to diagnose, treat, cure or prevent any disease, and these statements have not been evaluated by the FDA. Prescription options need a licensed clinician. Talk to your clinician or pharmacist before starting anything new, especially if you take prescription medicines, are pregnant or breastfeeding.

Keep reading: Menopause and HRT

Menopause and HRT: every page →Women's hormone telehealth compared →Browse all topics →

Previous in this topicVaginal Probiotics vs Placebo: What the Trials Show for BV and Yeast InfectionsA vaginal Lactobacillus crispatus product cut BV recurrence in a 2020 trial, but it is not on the market.Next in this topicWomen's Hair Loss: Minoxidil, Spironolactone, Laser Caps and Supplements, by the EvidenceTopical minoxidil has the best evidence for female pattern hair loss, and low-dose oral minoxidil matched it in a pooled analysis of trials.Minoxidil for Women: Topical Foam vs Low-Dose Pills, by the TrialsTopical minoxidil roughly doubled the odds of noticeable regrowth vs placebo in women.Spironolactone for Female Pattern Hair Loss: What the Evidence ShowsSpironolactone is prescribed off-label for female pattern hair loss.Hair Loss Supplements for Women: Biotin, Nutrafol and What the Trials ShowBiotin helps hair mainly in people who are deficient, and it can distort some lab tests.

Menopause treatment cost →3 a.m. waking in menopause →